Some Breast Cancer Patients May Not Need Node Dissection

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 4
Volume 6
Issue 4

BERN, Switzerland--A study of 1,619 breast cancer patients has identified a population subset with a very low incidence of lymph node metastases in whom axillary lymph node dissection might be omitted, Andreas Barth, MD, told Oncology News International.

BERN, Switzerland--A study of 1,619 breast cancer patients has identifieda population subset with a very low incidence of lymph node metastasesin whom axillary lymph node dissection might be omitted, Andreas Barth,MD, told Oncology News International.

This series of patients was comprised of those with T1-T4 breast cancerwho underwent level I/II axillary dissection between 1979 and 1995 at TheBreast Center, Van Nuys, Calif. Analysis of 11 clinical/pathological factorsshowed that patients with nonpalpable, non-high grade tumors of less than10 mm, with no lymph-vascular space involvement had an incidence of lymphnode metastases of only 3%.

"In these patients, a lymph node dissection could be omitted, especiallyif they are postmenopausal and ER positive," said Dr. Barth, of theInstitute of Medical Oncology, Bern, Switzerland. Dr. Barth worked on thestudy under Dr. Melvin Silverstein during a fellowship at Van Nuys, andpresented the data at the San Antonio Breast Cancer Symposium.

He pointed out that this population subset comprises only about 7% ofall breast cancer patients, "so it doesn't solve the problem for about93%, and that's where newer techniques, like the sentinel lymph node biopsy,might come in."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.